October 22, 2011

Alemtuzumab (Lemtrada™*) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study

- New data from CARE-MS I presented at the 5th ECTRIMS/ACTRIMS Congress -
- Data shows 78 percent of patients treated with alemtuzumab remained relapse-free for two years compared with patients on high dose IFNβ-1a -

 

Alemtuzumab (Lemtrada™*) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study
- New data from CARE-MS I presented at the 5th ECTRIMS/ACTRIMS Congress -
- Data shows 78 percent of patients treated with alemtuzumab remained relapse-free for two years compared with patients on high dose IFNβ-1a -

Paris, France – October 22, 2011 – Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today new results from the CARE-MS I trial, the first of two randomized, Phase III clinical trials comparing the investigational drug alemtuzumab (Lemtrada™) to Rebif® (high dose subcutaneous interferon beta-1a) in patients with relapsing-remitting multiple sclerosis (MS). New data show that 78 percent of patients treated with alemtuzumab remained relapse-free for two years, providing statistically significant improvement over interferon beta-1a (78 percent vs 59 percent at two years, p<0.0001) and meeting this secondary endpoint. The CARE-MS I results were presented today at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS). Genzyme is developing alemtuzumab for relapsing MS in collaboration with Bayer HealthCare.